These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 25846027)

  • 21. Re: The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy I. M. Thompson, C. M. Tangen, D. P. Ankerst, C. Chi, M. S. Lucia, P. Goodman, H. Parnes and C. A. Coltman, Jr. J Urol 2008; 180: 544-547.
    Atmaca AF; Balbay MD
    J Urol; 2009 May; 181(5):2387-8. PubMed ID: 19303084
    [No Abstract]   [Full Text] [Related]  

  • 22. [Evaluation of (-2)proPSA in combination with total PSA and free PSA for the early detection of prostate cancer].
    Lamy PJ; Montels F; Tosi D; Leizour B; Bascoul-Mollevi C; Castan F; Roques S; Nielloud F; Rebillard X
    Ann Biol Clin (Paris); 2013; 71(5):537-44. PubMed ID: 24113439
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor-associated forms of prostate specific antigen improve the discrimination of prostate cancer from benign disease.
    Mikolajczyk SD; Rittenhouse HG
    Rinsho Byori; 2004 Mar; 52(3):223-30. PubMed ID: 15137320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Re: Correction of prostate-specific antigen velocity for variation may improve prediction of cancer following prostate repeat biopsy.
    Singh A
    Can J Urol; 2009 Jun; 16(3):4659. PubMed ID: 19497173
    [No Abstract]   [Full Text] [Related]  

  • 25. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection.
    Jansen FH; van Schaik RH; Kurstjens J; Horninger W; Klocker H; Bektic J; Wildhagen MF; Roobol MJ; Bangma CH; Bartsch G
    Eur Urol; 2010 Jun; 57(6):921-7. PubMed ID: 20189711
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Re: Giorgio Guazzoni, Massimo Lazzeri, Luciano Nava, et al. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and Prostate Health Index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer. Eur Urol 2012;61:455-66.
    Tadtayev S; McNicholas TA; Boustead GB
    Eur Urol; 2012 Jul; 62(1):e14-5; author reply e16-7. PubMed ID: 22537798
    [No Abstract]   [Full Text] [Related]  

  • 27. The influence of prostate volume in prostate health index performance in patients with total PSA lower than 10 μg/L.
    Filella X; Foj L; Alcover J; Augé JM; Molina R; Jiménez W
    Clin Chim Acta; 2014 Sep; 436():303-7. PubMed ID: 24978824
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of precursor prostate-specific antigen isoform ratios in the detection of prostate cancer.
    Naya Y; Fritsche HA; Bhadkamkar VA; Mikolajczyk SD; Rittenhouse HG; Babaian RJ
    Urol Oncol; 2005; 23(1):16-21. PubMed ID: 15885578
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Volume-based evaluation of serum assays for new prostate-specific antigen isoforms in the detection of prostate cancer.
    Naya Y; Fritsche HA; Bhadkamkar VA; Mikolajczyk SD; Rittenhouse HG; Babaian RJ
    Urology; 2004 Mar; 63(3):492-8. PubMed ID: 15028444
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Re: Martin Spahn, Steven Joniau, Paolo Gontero, et al. Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients. Eur Urol 2010;58:1-7.
    Neulander EZ; Wejsman Z
    Eur Urol; 2010 Sep; 58(3):e36; author reply e37-8. PubMed ID: 20605673
    [No Abstract]   [Full Text] [Related]  

  • 31. p2PSA but not total and free PSA increases after myocardial infarction: results of a preliminary investigation.
    Lippi G; Aloe R; Cervellin G
    Int J Cardiol; 2011 Nov; 153(1):119. PubMed ID: 21968074
    [No Abstract]   [Full Text] [Related]  

  • 32. Editorial comment. ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program.
    Bartoletti R; Cai T
    Urology; 2011 Mar; 77(3):e1; author reply e2. PubMed ID: 21376994
    [No Abstract]   [Full Text] [Related]  

  • 33. Head-to-head comparison of prostate health index and urinary PCA3 for predicting cancer at initial or repeat biopsy.
    Scattoni V; Lazzeri M; Lughezzani G; De Luca S; Passera R; Bollito E; Randone D; Abdollah F; Capitanio U; Larcher A; Lista G; Gadda GM; Bini V; Montorsi F; Guazzoni G
    J Urol; 2013 Aug; 190(2):496-501. PubMed ID: 23466239
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A multicenter clinical trial on the use of (-5, -7) pro prostate specific antigen.
    Lein M; Semjonow A; Graefen M; Kwiatkowski M; Abramjuk C; Stephan C; Haese A; Chun F; Schnorr D; Loening SA; Jung K
    J Urol; 2005 Dec; 174(6):2150-3. PubMed ID: 16280753
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Re: The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?
    Rosser CJ; Parker A
    J Urol; 2005 Sep; 174(3):1154-5; author reply 1155-6. PubMed ID: 16094093
    [No Abstract]   [Full Text] [Related]  

  • 36. Editorial Comment to Postoperative prostate-specific antigen nadir improves accuracy for predicting biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) and Duke Prostate Center databases.
    Viney R
    Int J Urol; 2010 Nov; 17(11):922-3. PubMed ID: 20969639
    [No Abstract]   [Full Text] [Related]  

  • 37. The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer.
    Whitson JM; Porten SP; Hilton JF; Cowan JE; Perez N; Cooperberg MR; Greene KL; Meng MV; Simko JP; Shinohara K; Carroll PR
    J Urol; 2011 May; 185(5):1656-60. PubMed ID: 21419438
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Diagnostic value of tissue and serum prostate specific antigen in prostate cancer].
    Medvedev VL
    Voen Med Zh; 2004 Feb; 325(2):50-4. PubMed ID: 15101295
    [No Abstract]   [Full Text] [Related]  

  • 39. How valuable is prostate-specific antigen screening?
    Handler S
    Minn Med; 1996 Jun; 79(6):2. PubMed ID: 8692130
    [No Abstract]   [Full Text] [Related]  

  • 40. From pro-prostate specific antigen, [-2]pro-prostate specific antigen to Beckman Coulter phi: the evolution of new biomarkers for early detection of prostatic carcinoma.
    Zhang MZ; Lu YP
    Chin Med J (Engl); 2012 May; 125(9):1643-9. PubMed ID: 22800836
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.